Themis Medicare Ltd - THEMIS MEDICARE Share Price

Sector: Pharmaceuticals | ISIN: INE083B01016
₹ 209.10 (-3.01%) icon15 Apr, 2024, 12:00:00 AM
Open
₹ 210.00
Prev. Close
₹ 215.60
Turnover(lac)
₹ 0.00
Day's High
₹ 214.50
Day's Low
₹ 203.00
52 Wk High
₹ 263.85
52 Wk Low
₹ 131.61
Book Value
₹ 29.30
Face Value
₹ 1.00
Mkt. Cap (Cr.)
₹ 1,924.56
P/E
69.72
EPS
3.01
Div. Yield
0.24

Themis Medicare Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/15/2024 12:00:00 AM

    ₹ 209.1 -6.50 -3.01
  • Open
  • ₹ 210
  • Prev. Close
  • ₹ 215.6
  • Turnover(Lac.)
  • ₹ 106
  • Day's High
  • ₹ 214.5
  • Day's Low
  • ₹ 203
  • 52 Week's High
  • ₹ 263.85
  • 52 Week's Low
  • ₹ 131.61
  • Book Value
  • ₹ 29.3
  • Face Value
  • ₹ 1
  • Mkt Cap (₹ Cr.)
  • 1,924.56
  • P/E
  • 69.72
  • EPS
  • 3.01
  • Divi. Yield
  • 0.24

Themis Medicare Ltd Corporate Actions

29 Jan , 2024

12:00 AM

29 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

25 Oct , 2023

12:00 AM

13 May , 2023

12:00 AM

13 May , 2023

12:00 AM

AGM

Announcement date: 13 May , 2023

View Details

07 Sep , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 May , 2023

12:00 AM

Dividend

Dividend amount: 5
Announcement date: 13 May , 2023

View Details

02 Aug , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

02 Aug , 2023

12:00 AM

04 May , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

13 May , 2023

12:00 AM

BookCloser

View Details

No Record Found


Themis Medicare Ltd News and Update

No Record Found

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Themis Medicare Ltd SHAREHOLDING SNAPSHOT
16 April , 2024 | 03:15 AM

PROMOTER - TOTAL67.16%

Indian: 57.55%

Foreign: 9.6092%

NON-PROMOTER - TOTAL 32.84%

Institutions: 0.03%

Non-Institutions: 32.82%

CUSTODIES - 0.00%

Custodies: 0.00%

See More Details
ad IconAd Image

Themis Medicare Ltd FINANCIALS

Themis Medicare Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Themis Medicare Ltd

  • Rajneesh Anand
  • Non-Exec & Non-Independent Dir
  • VIJAY GOPI KISHAN AGARWAL
  • Independent Non Exe. Director
  • Hari Subramaniam
  • Independent Non Exe. Director
  • Reena S Patel
  • Non Executive Director
  • Sachin D Patel
  • ED / MD / CEO / Promoter
  • Dinesh S Patel
  • Chairman & Independent Directo
  • Manjul Sandhu
  • Independent Non Exe. Director
  • Bhaskar Vemban Iyer
  • Independent Non Exe. Director
  • Shishir Dalal
  • Additional Director
  • Reena S Patel
  • Alternate Director

Summary

Incorporated in 1969, Themis Medicare Ltd., formerly known as Themis Chemicals (TCL) was originally promoted by Chemosyn and Medimpex but was taken over by a Group consisting of Shantibhai D Patel and K T Lakdawala who also have interests in Andhra Synthetics and Antibiotics, which was merged with Artemis Pharmaceuticals in April 93. The Group is principally engaged in the activities pertaining to manufacturing of pharmaceutical products, especially in Formulation and API activity.In Mar.95, the company came out with a public issue equity shares (premium : Rs 110) to finance the expansion-cum-modernisation of its synthetic bulk drug plant at Vapi, the setting up of a formulation unit at Lilora, Baroda as backward integration and to augment long-term working capital.Total cost of the project was estimated at Rs 17.64 cr. TCL manufactures and sells synthetic bulk drugs and formulations. It operates in the therapeutic segments of anti-tuberculosis, cerebroactivators, bronchodilators, anti-asthmatic, anaesthetic and other segments.Anti-tuberculosis bulk drugs and formulations account for 60% of its turnover and the company is rated fourth in terms of turnover in this segment. TCL has also started manufacturing and exporting fumagillin, an anti-bacterial drug, for veterinary use for which it has a confirmed buy-back arrangement with Chinoin, Hungary.The company with the help of M/s Pharmograd,Moscow a manufacturing unit, is planning to market its Anti-T.B.formulation products... Read More


Reports by Themis Medicare Ltd


Reports by Themis Medicare Ltd

Company FAQ

No Record Found